Mursla Bio

About Mursla Bio

Mursla Bio is a biotech company on a mission to significantly improve chronic disease outcomes for at-risk patients through the power of Dynamic Biopsy. The Company’s proprietary biopsy platform non-invasively analyzes living biological processes within a specific organ or tissue to assess its health condition. This approach combines the accuracy and disease sub-typing capabilities of tissue biopsies with the ease of liquid biopsy sample collection. Dynamic Biopsy is made possible by advanced extracellular vesicle (EV) science and an innovative approach called extracellular omics, supported by Mursla Bio’s pioneering technologies. These technologies include physical organ-specific EV isolation from biofluids for precise targeting, an AI-enabled multi-omics workflow spanning across proteins, miRNAs and mRNAs and a scalable clinical assay platform optimized for clinical validity and utility. The Company’s AI Precision Medicine Platform underpins this technology, offering a full-stack infrastructure for biomarker discovery, assay development, and precision diagnostic productization across disease areas, grounded in real-world clinical datasets rather than static tissue atlases. Mursla Bio is initially focused on transforming the surveillance of liver cancer in high-risk populations - the fastest growing cause of cancer related deaths. Mursla Bio is developing its first Dynamic Biopsy-based blood test, EvoLiver™ alongside synergistic precision medicine applications in hepatology. Mursla Bio is based in Cambridge, UK and Boston, MA.